Relationship Between Efavirenz Trough & CYP2B6 Genotypes with Rifampin-Based TB Therapy in STRIDE
Background: Rifampin(RIF) induces cytochrome P450 (CYP) isoforms, which can lower plasma EFV exposure. However, in STRIDE, RIF-containing tuberculosis therapy was associated with increased EFV Cmin. As CYP2B6 polymorphisms predict EFV exposure, we conducted a nested pharmacogenomics study to evaluate EFV Cmin by CYP2B metabolizer status in STRIDE participants. Methodology: EFV Cmin was measured by HPLC(LLQ…